IMEDICA SA

Their core work

IMEDICA is a Romanian medical SME specializing in brown adipose tissue (BAT) research and its therapeutic applications. Across all three of their H2020 projects, they have contributed industry expertise to academic-industry staff exchange programs (MSCA-RISE) focused on detecting, regenerating, and activating brown fat in humans. Their work spans non-invasive BAT measurement techniques, bio-scaffold tissue engineering, and nanotechnology-based approaches to stimulate BAT activity — all targeting obesity and metabolic disease treatment. As a private company embedded in research consortia, they likely provide clinical translation capability and commercial pathway development for BAT-related technologies.

What they specialise in

How they've shifted over time

IMEDICA's H2020 participation spans 2014–2016 project starts, all within a narrow thematic window. Their trajectory shows a progression from diagnostic approaches (non-invasive BAT estimation in ICI-THROUGH, 2014) toward increasingly interventional technologies — first tissue engineering (SCAFFY, 2015), then nanotechnology-based activation (nanoBAT, 2016). This suggests a deliberate shift from measuring brown fat to actively manipulating it for therapeutic purposes.

IMEDICA appears to be moving from diagnostic measurement toward therapeutic intervention in brown adipose tissue, making them a potential partner for translational metabolic health projects.

How they like to work

IMEDICA participates exclusively as a partner, never coordinating — consistent with an industry SME contributing commercial and translational perspective to academically-led research. All three projects used the MSCA-RISE scheme, which involves staff exchanges between sectors, suggesting IMEDICA values deep, embedded collaboration over arms-length subcontracting. With 11 unique partners across 7 countries from just 3 projects, they appear comfortable in diverse, multinational consortia.

IMEDICA has built a network of 11 consortium partners across 7 countries through its three MSCA-RISE projects. The thematic consistency across all projects suggests these partners likely form a tight-knit brown adipose tissue research community spanning multiple European countries.

What sets them apart

IMEDICA occupies a rare niche: a private SME deeply embedded in brown adipose tissue research, a field dominated by university labs. Their three consecutive MSCA-RISE projects covering BAT detection, regeneration, and nanotechnology-based activation give them unusually broad coverage of the BAT research landscape from an industry perspective. For any consortium needing a commercial partner to translate BAT science toward products or clinical applications, IMEDICA brings both the scientific understanding and the business orientation that academic-only teams typically lack.

Highlights from their portfolio

• ICI-THROUGH
  Largest funded project (EUR 207,000) and earliest, establishing IMEDICA's position in non-invasive brown adipose tissue measurement — a key diagnostic challenge in metabolic research.
• nanoBAT
  Most recent project combining nanotechnology with brown fat activation, representing the most interventional and commercially promising direction in their portfolio.